Progenics Pharmaceuticals, Inc. (PGNX) belonging to the Healthcare sector has surged 1.08% and closed its last trading session at $7.5.
The company reported its EPS on 12/30/2017. Currently, the stock has a 1 Year Price Target of $15.67.
The consensus recommendation, according to Zacks Investment research, is 1. The scale runs from 1 to 5 with 1 recommending Strong Buy and 5 recommending a Strong Sell.
The Stock had a 1 Consensus Analyst Recommendation 30 Days Ago, whereas 60 days ago and 90 days ago the analyst recommendations were 1 and 1 respectively.
Progenics Pharmaceuticals, Inc. on 12/30/2017 reported its EPS as $-0.23 with the analysts projecting the EPS of the stock as $-0.19. The company beat the analyst EPS Estimate with the difference of $-0.04. This shows a surprise factor of -0.211%.
Many analysts have provided their estimated foresights on Progenics Pharmaceuticals, Inc. Earnings, with 3 analysts believing the company would generate an Average Estimate of $-0.21.
Whereas they predicted High and Low Earnings Estimate as $-0.2 and $-0.23 respectively. While in the same Quarter Previous year, the Actual EPS was $-0.23.
Analysts are also projecting an Average Revenue Estimate for Progenics Pharmaceuticals, Inc. as $4350 in the Current Quarter. This estimate is provided by 4 analysts.
The High Revenue estimate is predicted as 4950, while the Low Revenue Estimate prediction stands at 4100. The company’s last year sales total was 2350.
Progenics Pharmaceuticals, Inc. (PGNX) has the market capitalization of $543.88 Million. The company rocked its 52-Week High of $8.63 and touched its 52-Week Low of $4.6.
The stock has Return on Assets (ROA) of -31.5 percent. Return on Equity (ROE) stands at -74.3% and Return on Investment (ROI) of -44.6 percent.
The stock is currently showing YTD performance of 26.05 Percent. The company has Beta Value of 2.56 and ATR value of 0.3. The Weekly and Monthly Volatility stands at 5.37% and 3.96%.